Maintenance treatment with the PARP inhibitor rucaparib (Rubraca) was well tolerated and provided clinical responses among patients with advanced BRCA- or PALB2-mutated pancreatic cancer sensitive to platinum-based chemotherapy,
(HealthDay)—Cimzia (certolizumab pegol) injection has been approved to treat adults with nonradiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation, the U.S. Food and Drug Administration announced. The
The Therapeutic Goods Administration (TGA) is currently looking to expand the list of medicines available “over the counter” – that is, via a pharmacist without a prescription. If
(HealthDay)—A safety statement was issued yesterday by the U.S. Food and Drug Administration regarding risks found to be associated with the investigational use of Venclexta (venetoclax) for treatment
The U.S. is reeling from a public health crisis driven by the misuse of prescription and illicit opioids with nearly 12 million people abusing the drugs annually. The
(HealthDay)—A safety clinical trial has revealed that tofacitinib (Xeljanz, Xeljanz XR) 10 mg twice daily is associated with an increased risk for pulmonary embolism (PE) and death among
There is an urgent need to identify reliable predictors of opioid responses to develop personalized opioid therapy for chronic pain management. A goal is to target opioid therapy
Scott Gottlieb, commissioner of the Food and Drug Administration, told The Washington Post this week that his agency will require drug companies to study whether opioids that are
Patients taking diuretics are often at risk for low potassium levels, which can put patients at an increased risk of death from cardiac arrhythmias or other causes. However,
(HealthDay)—Children who have surgery for a broken elbow may be overprescribed potentially addictive opioid painkillers, a new study finds. Overprescription includes giving kids too many opioids when they
We and our partners use cookies on this site to improve our service, perform analytics, personalize advertising, measure advertising performance, and remember website preferences.Ok
